Cargando…

Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography

Due to their very poor prognosis and a fatal outcome, secondary brain tumors are one of the biggest challenges in oncology today. From the point of view of the early diagnosis of these brain micro- and macro-tumors, the sensitivity and specificity of the diagnostic tools constitute an obstacle. Mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Moussaron, Albert, Jouan-Hureaux, Valérie, Collet, Charlotte, Pierson, Julien, Thomas, Noémie, Choulier, Laurence, Veran, Nicolas, Doyen, Matthieu, Arnoux, Philippe, Maskali, Fatiha, Dumas, Dominique, Acherar, Samir, Barberi-Heyob, Muriel, Frochot, Céline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659110/
https://www.ncbi.nlm.nih.gov/pubmed/34885871
http://dx.doi.org/10.3390/molecules26237273
_version_ 1784612888171773952
author Moussaron, Albert
Jouan-Hureaux, Valérie
Collet, Charlotte
Pierson, Julien
Thomas, Noémie
Choulier, Laurence
Veran, Nicolas
Doyen, Matthieu
Arnoux, Philippe
Maskali, Fatiha
Dumas, Dominique
Acherar, Samir
Barberi-Heyob, Muriel
Frochot, Céline
author_facet Moussaron, Albert
Jouan-Hureaux, Valérie
Collet, Charlotte
Pierson, Julien
Thomas, Noémie
Choulier, Laurence
Veran, Nicolas
Doyen, Matthieu
Arnoux, Philippe
Maskali, Fatiha
Dumas, Dominique
Acherar, Samir
Barberi-Heyob, Muriel
Frochot, Céline
author_sort Moussaron, Albert
collection PubMed
description Due to their very poor prognosis and a fatal outcome, secondary brain tumors are one of the biggest challenges in oncology today. From the point of view of the early diagnosis of these brain micro- and macro-tumors, the sensitivity and specificity of the diagnostic tools constitute an obstacle. Molecular imaging, such as Positron Emission Tomography (PET), is a promising technique but remains limited in the search for cerebral localizations, given the commercially available radiotracers. Indeed, the [(18)F]FDG PET remains constrained by the physiological fixation of the cerebral cortex, which hinders the visualization of cerebral metastases. Tumor angiogenesis is recognized as a crucial phenomenon in the progression of malignant tumors and is correlated with overexpression of the neuropilin-1 (NRP-1) receptor. Here, we describe the synthesis and the photophysical properties of the new gallium-68 radiolabeled peptide to target NRP-1. The KDKPPR peptide was coupled with gallium-68 anchored into a bifunctional NODAGA chelating agent, as well as Cy5 for fluorescence detection. The Cy5 absorbance spectra did not change, whereas the molar extinction coefficient (ε) decreased drastically. An enhancement of the fluorescence quantum yield (φ(F)) could be observed due to the better water solubility of Cy5. [(68)Ga]Ga-NODAGA-K(Cy5)DKPPR was radiosynthesized efficiently, presented hydrophilic properties (log D = −1.86), and had high in vitro stability (>120 min). The molecular affinity and the cytotoxicity of this new chelated radiotracer were evaluated in vitro on endothelial cells (HUVEC) and MDA-MB-231 cancer cells (hormone-independent and triple-negative line) and in vivo on a brain model of metastasis in a nude rat using the MDA-MB-231 cell line. No in vitro toxicity has been observed. The in vivo preliminary experiments showed promising results, with a high contrast between the healthy brain and metastatic foci for [(68)Ga]Ga-NODAGA-K(Cy5)DKPPR.
format Online
Article
Text
id pubmed-8659110
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86591102021-12-10 Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography Moussaron, Albert Jouan-Hureaux, Valérie Collet, Charlotte Pierson, Julien Thomas, Noémie Choulier, Laurence Veran, Nicolas Doyen, Matthieu Arnoux, Philippe Maskali, Fatiha Dumas, Dominique Acherar, Samir Barberi-Heyob, Muriel Frochot, Céline Molecules Article Due to their very poor prognosis and a fatal outcome, secondary brain tumors are one of the biggest challenges in oncology today. From the point of view of the early diagnosis of these brain micro- and macro-tumors, the sensitivity and specificity of the diagnostic tools constitute an obstacle. Molecular imaging, such as Positron Emission Tomography (PET), is a promising technique but remains limited in the search for cerebral localizations, given the commercially available radiotracers. Indeed, the [(18)F]FDG PET remains constrained by the physiological fixation of the cerebral cortex, which hinders the visualization of cerebral metastases. Tumor angiogenesis is recognized as a crucial phenomenon in the progression of malignant tumors and is correlated with overexpression of the neuropilin-1 (NRP-1) receptor. Here, we describe the synthesis and the photophysical properties of the new gallium-68 radiolabeled peptide to target NRP-1. The KDKPPR peptide was coupled with gallium-68 anchored into a bifunctional NODAGA chelating agent, as well as Cy5 for fluorescence detection. The Cy5 absorbance spectra did not change, whereas the molar extinction coefficient (ε) decreased drastically. An enhancement of the fluorescence quantum yield (φ(F)) could be observed due to the better water solubility of Cy5. [(68)Ga]Ga-NODAGA-K(Cy5)DKPPR was radiosynthesized efficiently, presented hydrophilic properties (log D = −1.86), and had high in vitro stability (>120 min). The molecular affinity and the cytotoxicity of this new chelated radiotracer were evaluated in vitro on endothelial cells (HUVEC) and MDA-MB-231 cancer cells (hormone-independent and triple-negative line) and in vivo on a brain model of metastasis in a nude rat using the MDA-MB-231 cell line. No in vitro toxicity has been observed. The in vivo preliminary experiments showed promising results, with a high contrast between the healthy brain and metastatic foci for [(68)Ga]Ga-NODAGA-K(Cy5)DKPPR. MDPI 2021-11-30 /pmc/articles/PMC8659110/ /pubmed/34885871 http://dx.doi.org/10.3390/molecules26237273 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Moussaron, Albert
Jouan-Hureaux, Valérie
Collet, Charlotte
Pierson, Julien
Thomas, Noémie
Choulier, Laurence
Veran, Nicolas
Doyen, Matthieu
Arnoux, Philippe
Maskali, Fatiha
Dumas, Dominique
Acherar, Samir
Barberi-Heyob, Muriel
Frochot, Céline
Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography
title Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography
title_full Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography
title_fullStr Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography
title_full_unstemmed Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography
title_short Preliminary Study of New Gallium-68 Radiolabeled Peptide Targeting NRP-1 to Detect Brain Metastases by Positron Emission Tomography
title_sort preliminary study of new gallium-68 radiolabeled peptide targeting nrp-1 to detect brain metastases by positron emission tomography
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8659110/
https://www.ncbi.nlm.nih.gov/pubmed/34885871
http://dx.doi.org/10.3390/molecules26237273
work_keys_str_mv AT moussaronalbert preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT jouanhureauxvalerie preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT colletcharlotte preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT piersonjulien preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT thomasnoemie preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT choulierlaurence preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT verannicolas preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT doyenmatthieu preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT arnouxphilippe preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT maskalifatiha preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT dumasdominique preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT acherarsamir preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT barberiheyobmuriel preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography
AT frochotceline preliminarystudyofnewgallium68radiolabeledpeptidetargetingnrp1todetectbrainmetastasesbypositronemissiontomography